Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesThe efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: A systematic review
Cancer Treatment Reviews, 07/20/09
Rollig C et al. – With respect to the higher evidence level of new substances such as bortezomib or lenalidomide, at present ATO has no role in routine management of relapsed or refractory myeloma.
Related Articles
Hyperlipidemic myeloma: review of 53 cases
Annals of Hematology, 11/25/09
Relevance Score: 94%
Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry
Acta Haematologica, 11/04/09
Relevance Score: 89%
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Journal of Clinical Oncology, 10/02/09
Relevance Score: 89%
Characteristics of Orbital Multiple Myeloma: A Case Report and Literature Review
Survey of Ophthalmology, 10/23/09
Relevance Score: 88%
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Leukemia, 10/05/09
Relevance Score: 88%
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Targeting EXT-1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma
Blood, 11/30/09
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma
Blood, 11/30/09
International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
Blood, 11/25/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
The Lancet Oncology - Online First, 11/30/09
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
The Lancet Oncology - Online First, 11/30/09
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review
Journal of Clinical Oncology, 11/30/09
Sponsor
Article Search
Sponsor
Sponsor